Daniels believes that President Trump could use tariffs to force the US pharmaceutical industry to work with other drug production democracies.
President Donald Trump He has recently bothered the import tariffs, and his government began to increase the probe this week.
The government said the tariffs are needed to restore drug production to the United States, which classify it as a national security issue. This comes as the AI Exiger chain alerts US confidence in Chinese -made drugs.
In the Exiger report, “A Bitter Tablet: A Dangerous US Dependence on China's drugs”, the company explains that American patients under the current system are not at risk of taking low quality drugs-or at all.
President Donald Trump said he would target the pharmaceutical industry at tariffs. (Getty Images / Getty Images)
Trump's manager moves toward semiconductor and pharmaceutical tariffs
“We were worried about the fact that after this epidemic, strategic efforts of national storage and the type of recovery, you know that US independence was somehow lost when both drugs and medical devices were somehow lost,” he told Fox Business. He also said that the elderly and those who rely on sensitive general drugs are more at risk of suffering from the problems of the current drug import system.
According to Exiger, the US is currently entering 75 % of it Basic medicinesWith most of them from China and India. While India produces about half of the general drugs that the United States imports, it relies on China for 80 % of its active drug (API). More than 500 general drugs rely on APIs in a country, including diabetes and cardiac conditions as well as antibiotics.
Another factor that puts Americans at risk is the use of compulsory labor in pharmacy production. Exiger found that several suppliers, including Sinopharm, the Chemical Group of the Gajjiang Shinda, and the Gajjiang Chemical Export Company, trusted the Uighur mandatory work in Sin Kiang. Customs and border patrols are supposed to block forced labor. However, some still disappear.
In the Exiger report, the company explains that American patients are not at risk at the current system at all. (ISTOCK / ISTOCK)
Daniels talked to Fox Trade about the risks involved Mandatory work In the pharmaceutical industry, including ethics and product quality issues.
“Many of these sites, which seem to have compulsory work, are literally walking without shoes in amenities, dirty facilities, facilities that do not map, and are in accordance with the good standards of the production process that all our medicines need to be met,” Daniels told Fox Business.
The CEO of Exiger also pointed to an accident in which drug cargoes contain hydrogen cyanide.
In an accident 2023, the non -contaminated -infected eyes produced by Kilitch health care in India resulted in the loss of vision and permanent infections in some patients. According to the Exiger report, the staining compounds produced by Kilitch Healthcare have been used in various products of brands.
In its report, Exiger recommends that the United States create a national strategic warehouse for essential drugs, vaccines and the device. In addition, the company calls on the United States to diversify its supply chains, eliminate mandatory work, strengthen FDA supervision, and enhance the production of public medicines.
Trump administration said these tariffs are necessary to restore drug production to the United States (Jeffrey Greenberg / Global Pictures Group via Giti Pictures / Getty Pictures)
Get on the move by clicking Fox Business Here
“I think that when it comes to biotechnology, there is a way to produce more in the United States,” Daniels told Fox Business. “And we are still a power plant in terms of intellectual property of biotechnology, but I don't think that's only answer.”
The Ministry of Commerce began an investigation into the consequences of national security imports on April 1. Federal Registration NoticeThe human being said that it is investigating public and non -generic pharmaceutical products, medical interactions, APIs and other important components of the import.